|
Re: Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy
|
2
|
Resverlogix Corp.
|
Oct 04, 2023 01:49PM
|
|
Can we seek funding for this?
|
3
|
Resverlogix Corp.
|
Oct 04, 2023 07:59AM
|
|
Re: Resverlogix Announces a Favorable Outlook Based on New Cardiovascular Disease Treatment Guidelines for Patients with Type 2 Diabetes
|
5
|
Resverlogix Corp.
|
Aug 29, 2023 06:49PM
|
|
Re: Review of ZCC history
|
2
|
Zenith Epigenetics
|
Aug 29, 2023 10:37AM
|
|
Re: Long covid trials
|
2
|
Resverlogix Corp.
|
Aug 01, 2023 09:53AM
|
|
Re: Long Covid remains a big challenge
|
2
|
Resverlogix Corp.
|
Jul 25, 2023 01:02PM
|
|
Re: Long Covid remains a big challenge
|
|
Resverlogix Corp.
|
Jul 25, 2023 08:51AM
|
|
Re: Long Covid remains a big challenge
|
2
|
Resverlogix Corp.
|
Jul 25, 2023 07:34AM
|
|
Re: Additional Reports of Exempt Distribution
|
2
|
Zenith Epigenetics
|
Jul 25, 2023 07:31AM
|
|
Re: While we fiddle
|
3
|
Resverlogix Corp.
|
Jul 20, 2023 10:52AM
|
|
Re: For what it’s worth
|
4
|
Zenith Epigenetics
|
Jul 20, 2023 08:35AM
|
|
While we fiddle
|
5
|
Resverlogix Corp.
|
Jul 20, 2023 08:10AM
|
|
Re: For what it’s worth
|
3
|
Zenith Epigenetics
|
Jul 20, 2023 08:04AM
|
|
For what it’s worth
|
6
|
Zenith Epigenetics
|
Jul 19, 2023 10:06AM
|
|
Re: Link to 2023 AGM presentation is up
|
2
|
Resverlogix Corp.
|
Jun 21, 2023 01:34PM
|
|
Re: AGM
|
2
|
Resverlogix Corp.
|
Jun 20, 2023 09:31AM
|
|
Re: AGM
|
|
Resverlogix Corp.
|
Jun 20, 2023 08:02AM
|
|
AGM
|
|
Resverlogix Corp.
|
Jun 20, 2023 07:53AM
|
|
Re: Down 53% today
|
2
|
Zenith Epigenetics
|
Jun 08, 2023 10:52AM
|
|
Re: Down 53% today
|
3
|
Zenith Epigenetics
|
Jun 07, 2023 06:52PM
|
